Trial Profile
Tolerability and primary efficacy of CX516 in Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs CX 516 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 15 Oct 2005 New trial record.